Neurogene Inc.
NGNE
Rank in Stocks
#10642
Neurogene Inc. is dedicated to engineering transformative genetic treatments... Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Share Price
$23.93
Last synced: 2026-11-13
Market Cap
$662.76M
Change (1 day)
0.13%
Change (1 year)
12.03%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Neurogene Inc. (NGNE)
Category
Healthcare
EPS for Neurogene Inc. (NGNE)
EPS as of September 2026 TTM: $-5.57
According to Neurogene Inc.'s latest financial reports, its current EPS (TTM) is $-5.57. At the end of 2025 the company had an EPS of $-4.24, an increase over its 2024 EPS of $-4.28.
EPS history for Neurogene Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-5.57 | 31.37% |
| 2025 | $-4.24 | -0.93% |
| 2024 | $-4.28 | 51.24% |
| 2023 | $-2.83 | -34.19% |
| 2022 | $-4.30 | 367.39% |
| 2021 | $-0.92 | 43.75% |
| 2020 | $-0.64 | -75.10% |
| 2019 | $-2.57 | 91.79% |
| 2018 | $-1.34 | -37.38% |
| 2017 | $-2.14 | 9.18% |
| 2016 | $-1.96 | 13.29% |
| 2015 | $-1.73 | -37.09% |
| 2014 | $-2.75 | 216.09% |
| 2013 | $-0.87 | 12.99% |
| 2012 | $-0.77 | -26.67% |
| 2011 | $-1.05 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -84.02% |
US
|
|
| $15.66 | -381.15% |
US
|
|
| $-7.07 | 26.93% |
US
|
|
| $-5.29 | -5.03% |
AU
|
|
| $12.73 | -328.59% |
BE
|
Questions about Neurogene Inc.'s earnings per share (EPS)
What is Neurogene Inc.'s earnings per share (EPS)?
Neurogene Inc.'s earnings per share (EPS) over the last twelve months is $-5.57, as of Sep 2026.
What was Neurogene Inc.'s earnings per share (EPS) in 2025?
In 2025, Neurogene Inc.'s earnings per share (EPS) was $-4.24, compared with $-4.28 in 2024.
How has Neurogene Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Neurogene Inc.'s earnings per share (EPS) was highest in 2020 ($-0.64) and lowest in 2022 ($-4.30).
How does Neurogene Inc.'s earnings per share (EPS) compare with similar companies?
Neurogene Inc.'s earnings per share (EPS) ($-5.57) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.